ecancer catches up with Josep Tabernero on exploring new targets in GI cancer as well as the WIN Consortium launch of WINTHER, an original academic and international clinical trial

Aimed at exploring all aspects of the translational research continuum, from early detection through treatment to survivorship, this special 5-day…

New Herceptin® delivery method could vastly simplify breast cancer treatment A new method of delivering a commonly used breast cancer…

The Mass General Cancer Center hosted an international, multi-disciplinary workshop on March 4 and 5 to explore how advances in…

Receiving 6 M EUR in funding from the European Commission´s Horizon 2020 – the biggest EU Research and Innovation Programme,…

An initiative aimed at promoting collaborative research of excellence in oncology and, more specifically, recognizing the contributions of young cancer…

• Promising results from a Phase II study evidence the clinical gains of combinatorial therapy with BRAF inhibitors for patients…

VHIO scientists discover a common factor among different tumours in a patient with Li-Fraumeni syndrome further to whole-genome sequencing This…

VHIO and 27 other leading European Cancer Institutes are working together in a unique collaboration to share infrastructures and collaborate on projects to help advance cancer research and treatment: EurocanPlatform

Important advances in next-generation whole-genome sequencing for precision oncology have led to the development of multiplex panel testing for the…

Showcased during AACR´s 2017 Annual Meeting´s Opening Plenary: The Road to Cancer Cures – Discover, Predict, Prevent and Treat, Sunday…

• The findings of the study, headed by the Breast Cancer Group at the VALL D’HEBRON ONCOLOGY INSTITUTE (VHIO) in Barcelona, present a new treatment option for patients with metastatic breast cancer.

• Eribulin is the first drug in the last 10 years to have an impact on metastatic breast cancer survival rates without having to be combined.

• The drug improves survival rates by 20% and has a very good toxicity profile compared to other chemotherapy drugs.

• The objective of the Phase III clinical trial was to identify the efficacy of a new treatment strategy for metastatic breast cancer.
 

Source: American Association for Cancer Research (AACR) PHILADELPHIA — Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies,…

Abstract submission and Registration for the VHIO-Fritz Bender Foundation joint International Symposium on Progress Towards Individualized Cancer Treatments, 07 –…

SPECTAcolor – Screening Platform for Efficient Clinical Trials Access in Colorectal cancer, funded by a corporate social responsibility program of…

Officially announced today, Halaven ® (Eribulin) has received reimbursement approval from the Spanish Directorate General of Pharmacy and Health Products,…